Peptides for Critical Care

3 research peptides are currently studied for critical care. This guide ranks them by evidence strength and covers their mechanisms, safety profiles, and current clinical status.

Vasopressin, also known as arginine vasopressin (AVP), is a naturally occurring cyclic nonapeptide hormone with a molecular weight of approximately 1084.2 g/mol. Synthesized in the hypothalamus and secreted by the posterior pituitary gland, it plays a crucial role in maintaining water homeostasis and vascular tone. Through its action on V2 receptors, vasopressin enhances water reabsorption in the renal collecting ducts, while its interaction with V1a receptors promotes vasoconstriction. Research indicates that vasopressin is effective in managing vasodilatory shock, particularly in septic shock scenarios, where it may improve hemodynamic stability. Furthermore, it has been integrated into advanced cardiac life support algorithms for cardiac arrest, underscoring its clinical relevance. While the evidence supporting its use is strong, ongoing studies continue to explore optimal dosing strategies and long-term outcomes in diverse patient populations.

Terlipressin is a synthetic analog of vasopressin, with a molecular weight of approximately 1227.4 g/mol, functioning as a prodrug that is metabolized into lysine vasopressin. This compound has a long-standing history of clinical use in Europe, particularly for managing variceal bleeding and hepatorenal syndrome. Terlipressin exerts its effects primarily through V1a receptor activation, leading to splanchnic vasoconstriction, which can enhance renal perfusion in patients suffering from portal hypertension. Clinical studies have demonstrated its efficacy in improving renal function in patients with hepatorenal syndrome type 1, establishing it as the first FDA-approved therapy for this condition. Despite its strong evidence base, limitations exist, particularly concerning the need for careful patient selection and monitoring due to potential adverse effects associated with vasoconstriction.

Angiotensin II is an endogenous peptide consisting of eight amino acids (Asp-Arg-Val-Tyr-Ile-His-Pro-Phe) and has a molecular weight of approximately 1046.2 g/mol. It serves as a key effector in the renin-angiotensin-aldosterone system (RAAS) and is the only exogenous angiotensin II formulation approved for use as a vasopressor. This peptide has been shown to effectively raise blood pressure in patients experiencing catecholamine-resistant vasodilatory shock, making it a critical option in the management of severe hypotension. Clinical studies have indicated that angiotensin II can reduce the need for background vasopressor therapy, which is particularly beneficial in complex cases of shock. However, research also highlights the necessity for careful monitoring of hemodynamic responses to mitigate risks associated with excessive vasoconstriction and to optimize patient outcomes.